Pharma prepares for possible federal scrutiny tied to Sunshine Act

06/13/2013 | Financial Times (tiered subscription model)

Drugmakers, medtech companies and doctors could be subjected to federal investigations next year once the CMS implements the Sunshine Act, according to people familiar with the issue. Companies are rushing to establish data collection systems by Aug. 1. While payments in and of themselves wouldn't result in a legal case, they could spark an inquiry, a spokesman for the HHS Office of Inspector General said.

View Full Article in:

Financial Times (tiered subscription model)

Published in Briefs: